|
|
News Breaks | | | | February 27, 2013 | | 06:34 EDT |  | AVEO | Aveo Pharmaceuticals' NDA for tivozanib to be reviewed by FDA on May 2
AVEO and Astellas Pharma Global Development, a U.S. subsidiary of Tokyo-based Astellas Pharma, announced that the FDA's Oncologic Drugs Advisory Committee will review the company's New Drug Application for tivozanib for the treatment of patients with advanced renal cell carcinoma during the morning session of its meeting on May 2. ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer, and makes recommendations to the Commissioner of Food and Drugs. The review of the NDA is expected to be complete by July 28. Tivozanib is an investigational medicine and is not currently approved in any country. | |
|
News For AVEO From The Last 14 Days Check below for free stories on AVEO the last two weeks. |
|
|
| May 24, 2013 | | 09:25 EDT | | AVEO | On The Fly: Pre-market Movers
 Subscribe for More Information | | | May 23, 2013 | | 18:54 EDT | | AVEO | On The Fly: After Hours Movers
UP AFTER EARNINGS: Pandora (P), up 9%... Infoblox (BLOX) up 16.8%... Marvell (MRVL), up 7.3%. DOWN AFTER EARNINGS: Sears Holding (SHLD), down 11.6%... salesforce.com (CRM), down 6.2%... Gap (GPS), down 3.2%... Aeropostale (ARO), down 3.1%. ALSO LOWER: AVEO Pharmaceuticals (AVEO), down 12.9% after disclosing that its partner Astellas will not submit an EMA marketing application for tivozanib... Titan Machinery (TITN), down 12.4% after saying it sees first quarter earnings below consensus and the company cut its full-year earnings view. | | | 17:21 EDT | | AVEO | Aveo: Astellas will not submit EMA marketing application for tivozanib
Subscribe for More Information | | | 16:30 EDT | | AVEO | Aveo: Astellas informed company that it doesn't intend to fund future RCC trials
Subscribe for More Information | |
|
|
|
|
|
|
